GlassScriptPhysician profile
Jisha Mathew
NPI 1205478724
$3,132.53
in general payments reported to CMS, 2019-2025
27 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $169 · 2023: $433 · 2024: $1,275 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $607.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $497.21 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $265.99 | 2021-2025 | |
| Lilly USA, LLC | $238.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.73 | 2024-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $201.44 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $194.74 | 2023-2025 | |
| Glaxosmithkline, LLC. | $160.95 | 2023-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $119.65 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.06 | 2023-2024 | Xifaxan, Trulance |
| Hologic Sales and Service, LLC | $50.14 | 2024 | Aptima, Thinprep 2000 Processor |
| Currax Pharmaceuticals LLC | $49.02 | 2025 | Contrave |
| Abbott Laboratories | $45.40 | 2024-2025 | Freestyle Libre 3 |
| Ars Pharmaceuticals Operations, INC. | $44.56 | 2025 | Neffy |
| Amgen INC. | $43.80 | 2022-2024 | Repatha, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.99 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.16 | 2024 | Caplyta |
| Gilead Sciences, INC. | $39.25 | 2021 | |
| Inspire Medical Systems, INC. | $37.02 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $28.42 | 2025 | Capvaxive, Gardasil 9 |
| Alk-Abello, INC | $27.96 | 2023-2024 | Grastek, Odactra |
| Curonix LLC | $23.96 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Dexcom, INC. | $23.57 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $19.42 | 2022 | |
| Cranial Technologies, INC | $18.65 | 2021 | |
| Axsome Therapeutics, INC. | $15.14 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $15.04 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jisha Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.